Global Blood Therapeutics, Inc. GBT announced that the FDA has accepted the supplemental new drug application (“sNDA”) as well as a new drug application (“NDA”) for its only marketed drug, Oxbryta ...
BeyondSpring stock plunges after FDA says NDA for CIN treatment 'cannot be approved' in current form
Shares of BeyondSpring Inc. plunged 55.2% toward a record low in premarket trading Wednesday, after the biopharmaceutical company said that it has received a complete response letter (CRL) from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback